 Thinle Chodon
Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 17 | 2018 | 499 | 1.540 |
Why?
| | Cancer Vaccines | 5 | 2020 | 154 | 1.470 |
Why?
| | Immunotherapy, Adoptive | 8 | 2019 | 136 | 1.280 |
Why?
| | Receptors, Antigen, T-Cell | 10 | 2019 | 385 | 1.090 |
Why?
| | T-Lymphocytes | 8 | 2019 | 1257 | 1.020 |
Why?
| | MART-1 Antigen | 4 | 2018 | 22 | 0.860 |
Why?
| | Ovarian Neoplasms | 3 | 2022 | 671 | 0.780 |
Why?
| | Proto-Oncogene Proteins B-raf | 7 | 2014 | 132 | 0.780 |
Why?
| | Immunotherapy | 5 | 2020 | 568 | 0.770 |
Why?
| | Dendritic Cells | 3 | 2020 | 389 | 0.690 |
Why?
| | Tumor Microenvironment | 3 | 2022 | 318 | 0.680 |
Why?
| | Immunotherapy, Active | 2 | 2015 | 15 | 0.610 |
Why?
| | Antibodies, Monoclonal | 5 | 2015 | 1466 | 0.580 |
Why?
| | Skin Neoplasms | 6 | 2018 | 529 | 0.550 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 124 | 0.550 |
Why?
| | Antineoplastic Agents | 7 | 2016 | 2276 | 0.520 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2021 | 502 | 0.520 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2019 | 390 | 0.400 |
Why?
| | Antigens, Neoplasm | 3 | 2020 | 321 | 0.370 |
Why?
| | Indoles | 7 | 2014 | 323 | 0.330 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2018 | 334 | 0.310 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2014 | 553 | 0.300 |
Why?
| | Sulfonamides | 6 | 2014 | 312 | 0.300 |
Why?
| | Keloid | 2 | 2003 | 8 | 0.290 |
Why?
| | T-Lymphocyte Subsets | 2 | 2019 | 294 | 0.290 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2014 | 219 | 0.260 |
Why?
| | Carcinoma, Renal Cell | 2 | 2020 | 392 | 0.250 |
Why?
| | Neoplasms | 3 | 2015 | 2609 | 0.250 |
Why?
| | Positron-Emission Tomography | 2 | 2014 | 265 | 0.240 |
Why?
| | Lymphocytes | 3 | 2014 | 459 | 0.230 |
Why?
| | Monitoring, Immunologic | 1 | 2021 | 14 | 0.230 |
Why?
| | Kidney Neoplasms | 2 | 2020 | 580 | 0.230 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 47 | 0.230 |
Why?
| | Fibroblasts | 2 | 2003 | 703 | 0.220 |
Why?
| | Autocrine Communication | 1 | 2000 | 17 | 0.220 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 108 | 0.210 |
Why?
| | Transforming Growth Factor beta | 2 | 2003 | 275 | 0.200 |
Why?
| | Humans | 31 | 2022 | 80837 | 0.200 |
Why?
| | Genes, T-Cell Receptor | 1 | 2019 | 9 | 0.190 |
Why?
| | Cell Line, Tumor | 9 | 2019 | 2341 | 0.190 |
Why?
| | Transduction, Genetic | 3 | 2014 | 144 | 0.190 |
Why?
| | Apoptosis | 3 | 2014 | 1699 | 0.190 |
Why?
| | Protein Kinase Inhibitors | 5 | 2013 | 532 | 0.180 |
Why?
| | CTLA-4 Antigen | 3 | 2014 | 139 | 0.180 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2016 | 891 | 0.180 |
Why?
| | Antigens, CD | 2 | 2010 | 469 | 0.170 |
Why?
| | Female | 17 | 2022 | 43279 | 0.160 |
Why?
| | Neoplasm Metastasis | 4 | 2014 | 1021 | 0.160 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2014 | 239 | 0.160 |
Why?
| | Hematologic Neoplasms | 1 | 2019 | 283 | 0.150 |
Why?
| | Cell Cycle | 2 | 2015 | 504 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2013 | 311 | 0.150 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 791 | 0.150 |
Why?
| | Genes, Transgenic, Suicide | 1 | 2014 | 4 | 0.140 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2014 | 77 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2015 | 1628 | 0.130 |
Why?
| | Peptide Fragments | 2 | 2014 | 468 | 0.130 |
Why?
| | Carbonic Anhydrases | 1 | 2013 | 13 | 0.130 |
Why?
| | Neoplasm Proteins | 2 | 2010 | 529 | 0.130 |
Why?
| | Natural Killer T-Cells | 1 | 2013 | 62 | 0.130 |
Why?
| | Hematopoietic Stem Cells | 1 | 2014 | 279 | 0.120 |
Why?
| | Vaccination | 1 | 2014 | 225 | 0.120 |
Why?
| | Cells, Cultured | 5 | 2018 | 2842 | 0.120 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2010 | 147 | 0.120 |
Why?
| | Gene Amplification | 1 | 2012 | 125 | 0.120 |
Why?
| | Neoplasm Staging | 2 | 2014 | 1872 | 0.110 |
Why?
| | Herpesvirus 1, Human | 1 | 2014 | 238 | 0.110 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2011 | 18 | 0.110 |
Why?
| | Signal Transduction | 2 | 2014 | 3177 | 0.110 |
Why?
| | Mice | 7 | 2022 | 10750 | 0.110 |
Why?
| | Animals | 8 | 2022 | 26046 | 0.110 |
Why?
| | Antibodies, Blocking | 1 | 2010 | 21 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2020 | 7653 | 0.110 |
Why?
| | Middle Aged | 10 | 2018 | 24750 | 0.110 |
Why?
| | Genes, ras | 1 | 2010 | 97 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2010 | 158 | 0.100 |
Why?
| | Protein Engineering | 1 | 2010 | 128 | 0.100 |
Why?
| | Epitopes | 1 | 2010 | 303 | 0.100 |
Why?
| | Male | 12 | 2018 | 40407 | 0.100 |
Why?
| | Adult | 9 | 2018 | 25137 | 0.100 |
Why?
| | Cell Survival | 3 | 2019 | 968 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 3 | 2014 | 197 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2010 | 1164 | 0.080 |
Why?
| | Antibodies | 2 | 2013 | 364 | 0.070 |
Why?
| | Enzyme Activation | 2 | 2010 | 702 | 0.070 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2003 | 82 | 0.070 |
Why?
| | Aged | 7 | 2018 | 17903 | 0.070 |
Why?
| | Caspases | 2 | 2002 | 162 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2479 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 197 | 0.060 |
Why?
| | Gelsolin | 1 | 2002 | 10 | 0.060 |
Why?
| | Keratinocytes | 1 | 2003 | 127 | 0.060 |
Why?
| | Cell Communication | 1 | 2003 | 177 | 0.060 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 2 | 2013 | 27 | 0.060 |
Why?
| | Lymphocyte Count | 2 | 2014 | 97 | 0.060 |
Why?
| | NAD | 1 | 2022 | 73 | 0.060 |
Why?
| | Tryptophan | 1 | 2022 | 83 | 0.060 |
Why?
| | bcl-X Protein | 1 | 2000 | 47 | 0.050 |
Why?
| | Staurosporine | 1 | 2000 | 43 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 1 | 2000 | 59 | 0.050 |
Why?
| | HEK293 Cells | 2 | 2013 | 622 | 0.050 |
Why?
| | Drug Resistance | 1 | 2000 | 259 | 0.050 |
Why?
| | Coculture Techniques | 2 | 2014 | 150 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2014 | 856 | 0.050 |
Why?
| | Cytokines | 2 | 2014 | 737 | 0.050 |
Why?
| | Phenotype | 2 | 2018 | 2226 | 0.050 |
Why?
| | Disease Management | 1 | 2020 | 328 | 0.040 |
Why?
| | Cryopreservation | 1 | 2018 | 70 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 211 | 0.040 |
Why?
| | Mutation | 3 | 2014 | 3737 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2018 | 154 | 0.040 |
Why?
| | Base Sequence | 2 | 2012 | 2367 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2000 | 654 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2014 | 2195 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2021 | 1905 | 0.040 |
Why?
| | Cell Line | 2 | 2012 | 2488 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2013 | 6383 | 0.040 |
Why?
| | Up-Regulation | 2 | 2010 | 680 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2010 | 1536 | 0.030 |
Why?
| | Complementarity Determining Regions | 1 | 2014 | 25 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2016 | 163 | 0.030 |
Why?
| | Antigens, CD34 | 1 | 2014 | 155 | 0.030 |
Why?
| | Clonal Evolution | 1 | 2013 | 10 | 0.030 |
Why?
| | Oximes | 1 | 2013 | 19 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2014 | 48 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily A | 1 | 2013 | 3 | 0.030 |
Why?
| | Chemokine CCL1 | 1 | 2013 | 3 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 124 | 0.030 |
Why?
| | Fibrinogen | 1 | 2013 | 54 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2013 | 178 | 0.030 |
Why?
| | Proteome | 1 | 2014 | 103 | 0.030 |
Why?
| | Th1 Cells | 1 | 2013 | 155 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2013 | 122 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 360 | 0.030 |
Why?
| | ras Proteins | 1 | 2013 | 128 | 0.030 |
Why?
| | Lectins, C-Type | 1 | 2013 | 96 | 0.030 |
Why?
| | Imidazoles | 1 | 2013 | 162 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2014 | 431 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2014 | 99 | 0.030 |
Why?
| | Th2 Cells | 1 | 2013 | 141 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2014 | 267 | 0.030 |
Why?
| | Cell Adhesion Molecules | 1 | 2013 | 159 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2012 | 42 | 0.030 |
Why?
| | DNA Damage | 1 | 2014 | 337 | 0.030 |
Why?
| | Microchip Analytical Procedures | 1 | 2011 | 3 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 117 | 0.030 |
Why?
| | Exome | 1 | 2012 | 113 | 0.030 |
Why?
| | Melanoma, Experimental | 1 | 2012 | 100 | 0.030 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 282 | 0.030 |
Why?
| | K562 Cells | 1 | 2010 | 44 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 63 | 0.030 |
Why?
| | Benzimidazoles | 1 | 2012 | 130 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2010 | 184 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 174 | 0.030 |
Why?
| | Monophenol Monooxygenase | 1 | 2010 | 8 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2010 | 119 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2010 | 35 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 1036 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 96 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 1051 | 0.030 |
Why?
| | Computational Biology | 1 | 2014 | 511 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2010 | 293 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 259 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2010 | 252 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2010 | 182 | 0.030 |
Why?
| | Genetic Engineering | 1 | 2010 | 105 | 0.030 |
Why?
| | Intracellular Space | 1 | 2009 | 38 | 0.020 |
Why?
| | Interleukin-17 | 1 | 2009 | 67 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2010 | 203 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2012 | 1503 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 495 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 685 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 395 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1291 | 0.020 |
Why?
| | Autoimmunity | 1 | 2009 | 154 | 0.020 |
Why?
| | Macrophages | 1 | 2011 | 538 | 0.020 |
Why?
| | Kinetics | 1 | 2010 | 1570 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1169 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 1333 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1991 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 3076 | 0.020 |
Why?
| | Paracrine Communication | 1 | 2003 | 23 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2003 | 101 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 109 | 0.020 |
Why?
| | Caspase 8 | 1 | 2002 | 39 | 0.020 |
Why?
| | Caspase 9 | 1 | 2002 | 51 | 0.020 |
Why?
| | Mesentery | 1 | 2002 | 50 | 0.020 |
Why?
| | Nevus, Pigmented | 1 | 2002 | 50 | 0.020 |
Why?
| | Cell Division | 1 | 2003 | 724 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 798 | 0.010 |
Why?
| | Phosphorylation | 1 | 2003 | 1109 | 0.010 |
Why?
| | Skin | 1 | 2003 | 540 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2002 | 517 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2096 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 3079 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2002 | 1149 | 0.010 |
Why?
| | Child | 1 | 2003 | 6587 | 0.010 |
Why?
| | Adolescent | 1 | 2003 | 8878 | 0.010 |
Why?
|
|
Chodon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|